This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Messy Call for Matria

The honeymoon has clearly ended for Matria Healthcare (MATR - Get Report).

Just months after its celebrated marriage to a competitor, Matria has crushed its fans with a disappointing outlook for the future. Notably, the disease-management firm has already lost out on one major contract it was counting on.

Matria managed to hit first-quarter target, but issued new guidance that has left investors worried about the rest of the year. The company is now forecasting far less growth in the second quarter than the market had been anticipating. It is then counting on major second-half improvements to lift its performance for the entire year.

Some clearly have their doubts.

"It's just clear as a bell to me that the stock market doesn't believe" the full-year guidance, one investor said during a conference call on Friday morning. "Can you give us something here to hang on to? This is painful."

The stock, indeed, suffered a major fall. The shares -- which peaked at $45 just two months ago -- plunged 14% to a nine-month low of $30.30 on Friday.

Bridging the Gap

Still, Matria's first-quarter results looked strong.

Revenue more than doubled to $80.9 million -- just topping the consensus estimate -- following the recent acquisition of CorSolutions. Meanwhile, earnings jumped more than eightfold to $12 million. Operating profits of 16 cents a share met the consensus estimate exactly.

However, Matria's second-quarter guidance fell well below analyst expectations. The company is forecasting second-quarter revenue of $82 million to $84 million instead of the $92.5 million Wall Street had anticipated. It is also looking for second-quarter profits of 16 cents to 19 cents a share -- which is a far cry from the current 28-cent consensus estimate.

Even so, Matria has simply tightened its full-year guidance to a range that -- at the high end -- still includes Wall Street's $1.20 target. To hit its goals, Matria must double its first-half earnings in the second half of the year.

"I know you want some additional comfort that we're not down here hallucinating in terms of what we expect to do," Matria CEO Parker Petit acknowledged during Friday's conference call. "It's very doable because of the huge operating leverage that comes with every new revenue dollar. ... We're comfortable. If we weren't, we would be so signaling."

Banking on Business

Still, Matria also felt pretty comfortable about landing a major contract that it failed to get in the end.

"It was a nice piece of business we would have liked," Petit explained. But "we came out on the short end of the stick ... (So) we've taken that out of our forecast."

Matria indicated that it had tried -- but failed -- to win that contract away from competitor Healthways (HWAY - Get Report). The company said that it had emerged as one of two finalists for the business, before losing out on the contract about 10 days ago. Meanwhile, it said that CorSolutions recently lost "a fairly substantial employer-type" account that has been eliminated from its forecasts as well.

On a positive note, Matria did portray its second-quarter guidance as conservative and hinted at possible upside in both the near and long term. The company then went on to ask for investors' trust in the meantime.

"We're going to get plenty of business," Petit promised. "It's just not visible to you yet."

Meanwhile, Petit attempted to shoot down any notion that short-sellers -- who have been betting against the stock -- might be right about the company.

"There have been so many inaccuracies in those short reports," he said. "I don't even know how they get that information."

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
HWAY $17.52 -0.11%
MATR $7.20 3.00%
AAPL $128.70 -0.19%
FB $78.81 -0.23%
GOOG $540.78 0.54%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs